Alcon Inc. (NYSE:ALC) Poised For Near-Term Upside As Momentum Signals Strengthen

Alcon’s operational metrics and several technical indicators align toward a near-term recovery bias, while fundamentals show mixed margin pressure against healthy cash and manageable leverage. WMDST values the stock as fair-valued.

Recent News

On July 25, 2025 Alcon highlighted Unity VCS surgical innovations and clinical data ahead of the ASRS meeting running July 31–August 2. On August 1, 2025 the company planned to occupy new Fort Worth space as part of a $1.0M buildout. On September 3, 2025 Alcon completed the acquisition of LumiThera, adding the Valeda photobiomodulation system for dry AMD to its portfolio.

Technical Analysis

ADX / DI+/DI-: ADX registers 32.91, signalling a strong trend environment. DI+ shows a dip & reversal at 15.81 while DI- shows a peak & reversal at 35.63; both reversal signals imply waning downside pressure and a tilt toward bullish directional strength, supporting the near-term recovery narrative relative to the current valuation.

MACD: MACD stands at -1.98 with a dip & reversal and a signal line at -2.04; MACD has crossed above its signal line, confirming a shift to bullish momentum and reinforcing the directional cue from the directional indicators for short-term price pressure higher.

MRO: MRO at -34.14 with a peak & reversal indicates the price sits below the model target and offers upward potential; the negative MRO aligns with the momentum signals and supports an expectation of price convergence toward valuation-implied levels.

RSI and Price Positioning: RSI at 39.99 with a dip & reversal shows below-neutral momentum but room to rally. Price at $75.11 sits under the 50-day ($81.71) and 200-day ($87.12) averages while near the 20-day average ($75.79) and above the 1x lower Bollinger band ($73.99), suggesting mean-reversion upside if momentum continues.

Volatility / Volume: 42-day beta at 1.71 indicates elevated short-term sensitivity; 10-day avg volume roughly matches recent volume, implying liquidity adequate for momentum-driven moves without extreme volume divergence. SuperTrend upper at $76.98 provides a near-term resistance reference.

 


Fundamental Analysis

Profitability: EBIT of $250,000,000 yields an EBIT margin of 9.63%, below the industry peer mean of 14.86% and below the industry peer median of 20.38%. EBIT margin fell QoQ by 48.56% and fell YoY by 27.16%, indicating near-term margin contraction relative to recent periods.

Revenue & Earnings: Total revenue equals $2,596,000,000 with revenue growth reported at 4.97%; revenue growth year-over-year reads 230.50%. Reported EPS of $0.76 beat the estimate of $0.71 by $0.05, an EPS surprise of 7.04%.

Cash Flow & Liquidity: Free cash flow equals $232,000,000 with a free cash flow yield of 0.55%. Cash and short-term investments total $1,408,000,000. Current ratio stands at 2.60 and quick ratio at 1.61, both reflecting adequate near-term liquidity. Cash conversion cycle at 192.71 days compares above the industry peer mean of 136.00 days, indicating longer working-capital duration.

Capital Structure: Total debt equals $5,251,000,000 with net debt $3,327,000,000. Debt-to-assets measures 16.73% and debt-to-equity 23.75%, consistent with modest leverage. Debt-to-EBITDA equals 21.00, reflecting a high coverage multiple driven by the current EBITDA base and warranting focus on cash generation trends.

Margins and Returns: Gross margin at 53.47% sits just below the industry peer mean of 57.20%. Return on equity is 0.80% and return on assets 0.56%, both depressed from prior periods (ROE QoQ down ~49.97%, ROA QoQ down ~50.57%), signaling margin and operating-pressure impacts on returns.

Valuation Metrics: P/E at 115.79 and forward P/E at 101.01 reflect elevated multiples relative to earnings; price-to-book at 1.93 sits below the industry peer mean of 4.42. Enterprise-value-to-revenue (EVR) at 17.89 and an enterprise multiple at 185.73 appear rich relative to operating cash metrics. WMDST values the stock as fair-valued, with high multiple levels balanced by cash, scale, and pipeline additions.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-19
NEXT REPORT DATE: 2025-11-19
CASH FLOW  Begin Period Cash Flow
 Operating Cash Flow
 Capital Expenditures
 Change In Working Capital
 Dividends Paid
 Cash Flow Delta
 End Period Cash Flow
 
INCOME STATEMENT REVENUE
 Total Revenue 2.6 B
 Forward Revenue 1.6 B
COSTS
 Cost Of Revenue 1.2 B
 Depreciation
 Depreciation and Amortization
 Research and Development 245.0 M
 Total Operating Expenses 2.3 B
PROFITABILITY
 Gross Profit 1.4 B
 EBITDA 250.0 M
 EBIT 250.0 M
 Operating Income 247.0 M
 Interest Income 4.0 M
 Interest Expense 51.0 M
 Net Interest Income -47.00 M
 Income Before Tax 199.0 M
 Tax Provision 23.0 M
 Tax Rate 11.6 %
 Net Income 176.0 M
 Net Income From Continuing Operations 176.0 M
EARNINGS
 EPS Estimate 0.71
 EPS Actual 0.76
 EPS Difference 0.05
 EPS Surprise 7.042 %
 Forward EPS 0.88
 
BALANCE SHEET ASSETS
 Total Assets 31.4 B
 Intangible Assets 18.4 B
 Net Tangible Assets 3.7 B
 Total Current Assets 6.3 B
 Cash and Short-Term Investments 1.4 B
 Cash 1.4 B
 Net Receivables 2.0 B
 Inventory 2.4 B
 Long-Term Investments 397.0 M
LIABILITIES
 Accounts Payable 895.0 M
 Short-Term Debt 71.0 M
 Total Current Liabilities 2.4 B
 Net Debt 3.3 B
 Total Debt 5.3 B
 Total Liabilities 9.3 B
EQUITY
 Total Equity 22.1 B
 Retained Earnings
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 44.73
 Shares Outstanding 494.400 M
 Revenue Per-Share 5.25
VALUATION
 Market Capitalization 42.6 B
 Enterprise Value 46.4 B
 Enterprise Multiple 185.731
Enterprise Multiple QoQ 69.994 %
Enterprise Multiple YoY 175.474 %
Enterprise Multiple IPRWA high: 234.897
ALC: 185.731
median: 76.655
mean: 61.469
low: -228.246
 EV/R 17.886
CAPITAL STRUCTURE
 Asset To Equity 1.419
 Asset To Liability 3.391
 Debt To Capital 0.192
 Debt To Assets 0.167
Debt To Assets QoQ -0.125 %
Debt To Assets YoY 3552.838 %
Debt To Assets IPRWA high: 1.297
mean: 0.247
ALC: 0.167
median: 0.16
low: 0.002
 Debt To Equity 0.237
Debt To Equity QoQ 0.589 %
Debt To Equity YoY 3558.706 %
Debt To Equity IPRWA high: 2.971
mean: 0.413
median: 0.266
ALC: 0.237
low: -1.733
PRICE-BASED VALUATION
 Price To Book (P/B) 1.926
Price To Book QoQ -9.461 %
Price To Book YoY -9.275 %
Price To Book IPRWA high: 17.161
median: 4.499
mean: 4.422
ALC: 1.926
low: -7.981
 Price To Earnings (P/E) 115.791
Price To Earnings QoQ -10.477 %
Price To Earnings YoY -4.926 %
Price To Earnings IPRWA high: 246.592
ALC: 115.791
median: 104.657
mean: 82.907
low: -204.468
 PE/G Ratio 28.173
 Price To Sales (P/S) 16.406
Price To Sales QoQ -13.316 %
Price To Sales YoY -7.884 %
Price To Sales IPRWA high: 154.906
mean: 21.101
median: 20.417
ALC: 16.406
low: 0.297
FORWARD MULTIPLES
Forward P/E 101.014
Forward PE/G 24.578
Forward P/S 26.547
EFFICIENCY OPERATIONAL
 Operating Leverage -9.249
ASSET & SALES
 Asset Turnover Ratio 0.083
Asset Turnover Ratio QoQ 3.225 %
Asset Turnover Ratio YoY -1.188 %
Asset Turnover Ratio IPRWA high: 0.482
mean: 0.164
median: 0.135
ALC: 0.083
low: 0.0
 Receivables Turnover 1.359
Receivables Turnover Ratio QoQ 1.154 %
Receivables Turnover Ratio YoY -0.595 %
Receivables Turnover Ratio IPRWA high: 3.864
mean: 1.501
median: 1.457
ALC: 1.359
low: 0.477
 Inventory Turnover 0.51
Inventory Turnover Ratio QoQ 7.879 %
Inventory Turnover Ratio YoY 5.71 %
Inventory Turnover Ratio IPRWA high: 3.161
mean: 0.755
median: 0.714
ALC: 0.51
low: 0.003
 Days Sales Outstanding (DSO) 67.137
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 192.71
Cash Conversion Cycle Days QoQ 1.274 %
Cash Conversion Cycle Days YoY 0.19 %
Cash Conversion Cycle Days IPRWA high: 401.407
ALC: 192.71
mean: 136.005
median: 114.45
low: -252.738
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.669
 CapEx To Revenue
 CapEx To Depreciation
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 26.8 B
 Net Invested Capital 26.8 B
 Invested Capital 26.8 B
 Net Tangible Assets 3.7 B
 Net Working Capital 3.9 B
LIQUIDITY
 Cash Ratio 0.581
 Current Ratio 2.601
Current Ratio QoQ -3.693 %
Current Ratio YoY 1.678 %
Current Ratio IPRWA high: 14.715
ALC: 2.601
mean: 2.233
median: 1.821
low: 0.353
 Quick Ratio 1.614
Quick Ratio QoQ -2.666 %
Quick Ratio YoY 3.322 %
Quick Ratio IPRWA high: 10.15
mean: 1.645
ALC: 1.614
median: 1.303
low: 0.411
COVERAGE & LEVERAGE
 Debt To EBITDA 21.004
 Cost Of Debt 0.863 %
 Interest Coverage Ratio 4.902
Interest Coverage Ratio QoQ -48.122 %
Interest Coverage Ratio YoY -25.728 %
Interest Coverage Ratio IPRWA high: 274.877
mean: 26.791
median: 18.769
ALC: 4.902
low: -384.45
 Operating Cash Flow Ratio 0.0
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 72.707
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 1.222 %
 Revenue Growth 4.974 %
Revenue Growth QoQ -529.163 %
Revenue Growth YoY 230.498 %
Revenue Growth IPRWA high: 47.668 %
mean: 7.653 %
median: 7.569 %
ALC: 4.974 %
low: -31.512 %
 Earnings Growth 4.11 %
Earnings Growth QoQ 195.896 %
Earnings Growth YoY -180.148 %
Earnings Growth IPRWA high: 200.0 %
median: 15.596 %
mean: 15.318 %
ALC: 4.11 %
low: -227.273 %
MARGINS
 Gross Margin 53.467 %
Gross Margin QoQ -4.393 %
Gross Margin YoY -2.872 %
Gross Margin IPRWA high: 94.498 %
mean: 57.203 %
median: 56.435 %
ALC: 53.467 %
low: 6.0 %
 EBIT Margin 9.63 %
EBIT Margin QoQ -48.563 %
EBIT Margin YoY -27.161 %
EBIT Margin IPRWA high: 33.87 %
median: 20.382 %
mean: 14.858 %
ALC: 9.63 %
low: -1000.426 %
 Return On Sales (ROS) 9.515 %
Return On Sales QoQ -49.177 %
Return On Sales YoY -28.031 %
Return On Sales IPRWA high: 35.533 %
median: 18.417 %
mean: 13.122 %
ALC: 9.515 %
low: -1349.836 %
CASH FLOW
 Free Cash Flow (FCF) 232.0 M
 Free Cash Flow Yield 0.545 %
Free Cash Flow Yield QoQ -33.537 %
Free Cash Flow Yield YoY -40.889 %
Free Cash Flow Yield IPRWA high: 11.539 %
mean: 0.749 %
median: 0.679 %
ALC: 0.545 %
low: -40.868 %
 Free Cash Growth -39.583 %
Free Cash Growth QoQ
Free Cash Growth YoY -136.969 %
Free Cash Growth IPRWA high: 337.277 %
mean: 12.185 %
median: -1.288 %
ALC: -39.583 %
low: -261.538 %
 Free Cash To Net Income 1.318
 Cash Flow Margin 0.0 %
 Cash Flow To Earnings 0.0
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 0.564 %
Return On Assets QoQ -50.57 %
Return On Assets YoY -25.0 %
Return On Assets IPRWA high: 19.773 %
median: 2.151 %
mean: 1.89 %
ALC: 0.564 %
low: -72.965 %
 Return On Capital Employed (ROCE) 0.863 %
 Return On Equity (ROE) 0.008
Return On Equity QoQ -49.969 %
Return On Equity YoY -25.258 %
Return On Equity IPRWA high: 0.769
median: 0.035
ALC: 0.008
mean: 0.002
low: -1.731
 DuPont ROE 0.798 %
 Return On Invested Capital (ROIC) 0.824 %
Return On Invested Capital QoQ -43.793 %
Return On Invested Capital YoY -103.877 %
Return On Invested Capital IPRWA high: 20.851 %
mean: 3.067 %
median: 2.936 %
ALC: 0.824 %
low: -30.099 %

Six-Week Outlook

Technical momentum has shifted toward bullish: directional indicators, a MACD cross above its signal, a negative MRO that implies price below model target, and an RSI with room to climb point to potential near-term upside toward the 50-day average near $81.71 and the SuperTrend resistance at $76.98. Margin compression and elevated multiples constrain fundamental catalysts; absent fresh material fundamental surprises, expect a momentum-led retracement toward moving averages over the next six weeks with heightened sensitivity to volume spikes and news flow (product launches, regulatory updates, or deal integration items).

About Alcon Inc.

Alcon AG (NYSE:ALC) leads the global eye care industry with a commitment to advancing vision health through innovative products and solutions. Established in 1945 and headquartered in Geneva, Switzerland, Alcon excels in the research, development, and distribution of cutting-edge eye care products. The company operates through two primary segments: Surgical and Vision Care. In the Surgical segment, Alcon delivers an extensive portfolio for eye surgeries, featuring advanced equipment, instrumentation, and diagnostics. Their offerings include intraocular lenses (IOLs), viscoelastics, and surgical solutions. Alcon’s pioneering technologies, such as the Centurion vision system, LenSx laser system, and NGENUITY 3D visualization system, aim to enhance surgical outcomes for cataract, vitreoretinal, and refractive procedures. The Vision Care segment focuses on providing a diverse range of contact lenses, from daily disposables to color-enhancing options, along with ocular health products. These products address conditions like dry eye, glaucoma, and ocular allergies, and include ocular vitamins and redness relievers. Alcon’s dedication to innovation and quality sets a benchmark in eye care, continuously improving the quality of life for eye care professionals and their patients globally.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.